Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5

Oncotarget

Volumn 4, Issue 12, 2013, Pages 2302-2316

  Exertier, Prisca ^a,b   Javerzat, Sophie ^a,b   Wang, Baigang ^c,f   Franco, Mélanie ^a,b   Herbert, John ^d   Platonova, Natalia ^a,b   Winandy, Marie ^e   Pujol, Nadège ^a,b   Nivelles, Olivier ^e   Ormenese, Sandra ^e   Godard, Virginie ^a,b   Becker, Jürgen ^f   Bicknell, Roy ^d   Pineau, Raphael ^a   Wilting, Jörg ^f   Bikfalvi, Andreas ^a,b   Hagedorn, Martin ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Angiogenesis; Eg5 kinesin; Ispinesib; Mklp2 kinesin; VEGF

Indexed keywords

KINESIN; PROTEIN EG5; PROTEIN KIF11; PROTEIN KIF20A; PROTEIN MKLP2; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE IDENTIFICATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLAST; MITOSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; TUMOR CELL; TUMOR CELL LINE; UPREGULATION; VASCULAR RING; ZEBRA FISH;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; GENE EXPRESSION; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KINESIN; MICE; MITOSIS; NEOVASCULARIZATION, PATHOLOGIC; QUINAZOLINES; RECOMBINANT PROTEINS; THIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZEBRAFISH;

EID: 84891943309     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1490     Document Type: Article

References (49)

1. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
2. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999; 13(1):9-22.
3. Tanne JH. FDA cancels approval for bevacizumab in advanced breast cancer. BMJ. 2011; 343:d7684.
4. Wilting J, Christ B and Weich HA. The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. Anatomy and embryology. 1992; 186(3):251-257.
5. Sarli V and Giannis A. Inhibitors of mitotic kinesins: next-generation antimitotics. ChemMedChem. 2006; 1(3):293-298.
6. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, Fischer S, Konstantinova I, Habermann B, Grabner H, Yaspo ML, Himmelbauer H, Korn B, Neugebauer K, Pisabarro MT and Buchholz F. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 2004; 432(7020):1036-1040.
7. Castillo A and Justice MJ. The kinesin related motor protein, Eg5, is essential for maintenance of pre-implantation embryogenesis. Biochemical and biophysical research communications. 2007; 357(3):694-699.
8. Chauviere M, Kress C and Kress M. Disruption of the mitotic kinesin Eg5 gene (Knsl1) results in early embryonic lethality. Biochemical and biophysical research communications. 2008; 372(4):513-519.
9. Hill E, Clarke M and Barr FA. The Rab6-binding kinesin, Rab6-KIFL, is required for cytokinesis. EMBO J. 2000; 19(21):5711-5719.
10. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC, Gonzales P, Roth S, Weitman S and Wood KW. Antitumor activity of a kinesin inhibitor. Cancer research. 2004; 64(9):3276-3280.
11. Basso AD, Liu M, Dai C, Gray K, Nale L, Tevar S, Lee S, Liang L, Ponery A, Yaremko B, Smith E, Tang H, Sheth PR, Siddiqui MA, Hicklin DJ and Kirschmeier P. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics. Molecular cancer therapeutics. 2010; 9(11):2993-3002.
12. Rath O and Kozielski F. Kinesins and cancer. Nat Rev Cancer. 2012; 12(8):527-539.
13. Orr GA, Verdier-Pinard P, McDaid H and Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003; 22(47):7280-7295.
14. Falnikar A, Tole S and Baas PW. Kinesin-5, a mitotic microtubule-associated motor protein, modulates neuronal migration. Molecular biology of the cell. 2011.
15. Sun XD, Shi XJ, Sun XO, Luo YG, Wu XJ, Yao CF, Yu HY, Li DW, Liu M and Zhou J. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5. Acta pharmacologica Sinica. 2011; 32(12):1543-1548.
16. Bartoli KM, Jakovljevic J, Woolford JL, Jr. and Saunders WS. Kinesin Molecular Motor Eg5 Functions during Polypeptide Synthesis. Molecular biology of the cell. 2011.
17. Midorikawa R, Takei Y and Hirokawa N. KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell. 2006; 125(2):371-383.
18. Hagedorn M, Balke M, Schmidt A, Bloch W, Kurz H, Javerzat S, Rousseau B, Wilting J and Bikfalvi A. VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dyn. 2004; 230(1):23-33.
19. Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A and Hagedorn M. Correlating global gene regulation to angiogenesis in the developing chick extra-embryonic vascular system. PLoS One. 2009; 4(11):e7856.
20. Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, Baranowski TC, Rubinstein AL, Doan TN, Dingledine R and Sandberg EM. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer research. 2007; 67(23):11386-11392.
21. Tcherniuk S, Skoufias DA, Labriere C, Rath O, Gueritte F, Guillou C and Kozielski F. Relocation of Aurora B and survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed Engl. 2010; 49(44):8228-8231.
22. Jin SW, Beis D, Mitchell T, Chen JN and Stainier DY. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development (Cambridge, England). 2005; 132(23):5199-5209.
23. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A and Bikfalvi A. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(5):1643-1648.
24. Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, Magnin N, Favereaux A, Maitre M, Gaiser T, von Deimling A, Czabanka M, Vajkoczy P, Chevet E, Bikfalvi A and Moenner M. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(35):15553-15558.
25. Herbert JM, Stekel D, Sanderson S, Heath VL and Bicknell R. A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics. 2008; 9:153.
26. Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW, 3rd and Su AI. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome biology. 2009; 10(11):R130.
27. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B and Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. Nature protocols. 2012; 7(1):89-104.
28. Chen AT and Zon LI. Zebrafish blood stem cells. Journal of cellular biochemistry. 2009; 108(1):35-42.
29. Wick N, Saharinen P, Saharinen J, Gurnhofer E, Steiner CW, Raab I, Stokic D, Giovanoli P, Buchsbaum S, Burchard A, Thurner S, Alitalo K and Kerjaschki D. Transcriptomal comparison of human dermal lymphatic endothelial cells ex vivo and in vitro. Physiol Genomics. 2007; 28(2):179-192.
30. Amatschek S, Kriehuber E, Bauer W, Reininger B, Meraner P, Wolpl A, Schweifer N, Haslinger C, Stingl G and Maurer D. Blood and lymphatic endothelial cell-specific differentiation programs are stringently controlled by the tissue environment. Blood. 2007; 109(11):4777-4785.
31. Pavlakovic H, Becker J, Albuquerque R, Wilting J and Ambati J. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Annals of the New York Academy of Sciences. 2010; 1207 Suppl 1:E7-15.
32. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, Vasist LS, Bowen CJ, Hodge JP, Dar MM and Ho PT. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer chemotherapy and pharmacology. 2011; 67(2):447-454.
33. Ostergaard P, Simpson MA, Mendola A, Vasudevan P, Connell FC, van Impel A, Moore AT, Loeys BL, Ghalamkarpour A, Onoufriadis A, Martinez-Corral I, Devery S, Leroy JG, van Laer L, Singer A, Bialer MG, et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. American journal of human genetics. 2012; 90(2):356-362.
34. Maliga Z and Mitchison TJ. Small-molecule and mutational analysis of allosteric Eg5 inhibition by monastrol. BMC chemical biology. 2006; 6:2.
35. Kaan HY, Ulaganathan V, Rath O, Prokopcova H, Dallinger D, Kappe CO and Kozielski F. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem. 2010; 53(15):5676-5683.
36. Jackson JR, Gilmartin A, Dhanak D, Knight S, Luo L, Sutton D, Caulder E, Diamond M, Giardiniere M, Zhang S, Huang P, Bergnes G, McDonald A, Lee Y, Sakowicz R and Wood KW. (2006). A second generation KSP inhibitor, SB-743921, is a highly potent and effective therapeutic in preclinical models of cancer. First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development (http://aacrmeetingabstractsorg/cgi/content/abstract/2006/2/B11): American Association for Cancer Research).
37. Chibon F, Lagarde P, Salas S, Perot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchere D, Blay JY, Collin F, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nature medicine. 2010; 16(7):781-787.
38. Gasnereau I, Boissan M, Margall-Ducos G, Couchy G, Wendum D, Bourgain-Guglielmetti F, Desdouets C, Lacombe ML, Zucman-Rossi J and Sobczak-Thepot J. KIF20A and Its Gene Product MKlp2 Are Increased During Hepatocyte Proliferation and Hepatocarcinogenesis. Am J Pathol. 2011.
39. Muller C, Gross D, Sarli V, Gartner M, Giannis A, Bernhardt G and Buschauer A. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer chemotherapy and pharmacology. 2007; 59(2):157-164.
40. Park JR, Eggert A and Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatric clinics of North America. 2008; 55(1):97-120, x.
41. Rossler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Suss R, Niemeyer CM and Vassal G. Angiogenesis as a target in neuroblastoma. Eur J Cancer. 2008; 44(12):1645-1656.
42. Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q, Zhang J and Ding S. The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Med Oncol. 2013; 30(1):476.
43. Ellis LM and Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-591.
44. Weisshardt P, Trarbach T, Durig J, Paul A, Reis H, Tilki D, Miroschnik I, Ergun S and Klein D. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab. Histochemistry and cell biology. 2012; 137(3):391-401.
45. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM and Xing HR. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Molecular cancer therapeutics. 2011; 10(7):1173-1184.
46. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR and Ruoslahti E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-1035.
47. Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang W and Lu SH. Kif18A is involved in human breast carcinogenesis. Carcinogenesis. 2010.
48. Taniwaki M, Takano A, Ishikawa N, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res. 2007; 13(22 Pt 1):6624-6631.
49. Takahashi S, Fusaki N, Ohta S, Iwahori Y, Iizuka Y, Inagawa K, Kawakami Y, Yoshida K and Toda M. Downregulation of KIF23 suppresses glioma proliferation. Journal of neuro-oncology. 2011.